Irbesartan Puren

Irbesartan, the active ingredient in Irbesartan Puren, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It is prescribed to treat hypertension and diabetic nephropathy in adult patients, helping to lower blood pressure and protect kidney function.

GNH USA supplies Irbesartan Puren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customers benefit from consistent batch release, comprehensive documentation, and responsive technical support.

Irbesartan, an angiotensin II receptor blocker, is used to manage conditions that involve the renin‑angiotensin system.

- Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of cardiovascular events. - Diabetic nephropathy: slows the progression of kidney damage in adults with type 2 diabetes, helping preserve renal function.

Common Side Effects: - Dizziness: light‑headed feeling, especially after standing quickly. - Headache: mild to moderate intensity. - Fatigue: general tiredness or lack of energy. - Cough: occasional dry cough. - Hyperkalemia: elevated blood potassium levels. - Nasal congestion: stuffy nose.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat that may impair breathing. - Acute renal failure: sudden loss of kidney function. - Hepatic injury: signs of liver damage such as jaundice. - Severe hypotension: markedly low blood pressure causing faintness. - Neutropenia: dangerously low white‑blood‑cell count. - Anaphylactic reaction: severe allergic response requiring immediate medical attention.

Patients should be monitored regularly while taking Irbesartan. - Blood pressure monitoring: ensure therapeutic targets are achieved without excessive lowering. - Renal function assessment: check serum creatinine and eGFR before and during therapy. - Serum potassium measurement: watch for hyperkalemia, especially when combined with potassium‑sparing agents. - Hepatic impairment caution: dose adjustment may be needed in patients with liver disease. - Pregnancy avoidance: discontinue if pregnancy is confirmed or planned. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines; clinicians should evaluate concomitant use.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use can increase the risk of renal impairment and hyperkalemia. - ACE inhibitors: concurrent therapy may lead to excessive potassium elevation and renal dysfunction. - Potassium‑sparing diuretics: increase the likelihood of hyperkalemia. - Lithium: Irbesartan can raise lithium concentrations, risking toxicity.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect, requiring blood pressure monitoring. - NSAIDs: can blunt the blood‑pressure‑lowering effect and affect renal function. - Cyclosporine: may increase serum Irbesartan levels, necessitating dosage review.